OTCMKTS:PHGUF

Pharming Group Q3 2026 Earnings Results & Report

Pharming Group logo
$1.26 0.00 (0.00%)
As of 11/13/2026

Pharming Group beat analyst earnings expectations and met on revenue in its Q3 2026 results, released October 27, 2026. The company reported EPS of $0.03 versus the $0.0210 consensus estimate, while revenue of $117.60 million matched the $117.60 million estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Pharming Group EPS Results

Actual EPS
$0.03
Consensus EPS
$0.0210
Beat/Miss
Beat by +$0.0090
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Pharming Group Revenue Results

Actual Revenue
$117.60 million
Expected Revenue
$117.60 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Conference Call Resources

Pharming Group Q3 2026 Earnings FAQ

Pharming Group (OTCMKTS:PHGUF) reported earnings of $0.03 per share for Q3 2026, beating the consensus estimate of $0.0210. The report was announced on Tuesday, October 27, 2026.

Pharming Group reported revenue of $117.60 million for Q3 2026, against a consensus estimate of $117.60 million.

Pharming Group Earnings Headlines

FDA clears next-gen therapy with 10 to 40 times greater potency
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.tc pixel
See More Pharming Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email.

About Pharming Group

Pharming Group (OTCMKTS:PHGUF) is a biotechnology company based in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases. Its portfolio includes treatments for hereditary angioedema and activated phosphoinositide 3-kinase delta syndrome (APDS).

The company’s products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks, and Joenja (leniolisib), an oral treatment for APDS. Pharming developed Ruconest using a production process involving genetically modified rabbits.

Founded in 1988, Pharming serves patients in markets including the United States and Europe, with additional access supported through commercial partners. Its work also includes research and development of medicines for other rare diseases.

View Pharming Group Profile